# Collegium Pharmaceutical, Inc. (COLL) · Edgar & Edgarette company card

> Collegium Pharmaceutical (COLL) grew revenue 23.6% in FY2025 to $781 million, operating margin 23.0% against a -3.8% median for pharmaceutical preparations, equity 18.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1267565 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/COLL) · [JSON](https://www.pops4.com/boards/company/COLL.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $781M |
| Revenue growth, 1 year | 23.6% |
| Revenue growth per year | 29.6% |
| Operating margin | 23.0% (prior year 26.9%) |
| Net margin | 8.1% |
| Operating cash flow | $329M |
| Capital spending | $2M |
| Free cash flow | $328M |
| Cash | $231M |
| Long-term debt | — |
| Total assets | $1.7B |
| Total equity | $302M |
| Equity ÷ assets | 18.2% |
| Return on equity | 20.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 1.76 (grey zone)
- Piotroski F: 7 of 9 (solid)
- Beneish M: -3.32 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $780.6M (FY2025). Experience: revenue up 23.6% on the year, up 29.6% a year over 4 years; operating margin 23.0%, down from 26.9%. Soundness: equity 18.2% of assets, return on equity 20.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $733.0M and $1.2B next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $650.1M to $1.3B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 23.0% against a -3.8% median; growth 23.6% against 13.7%.

Range logged 2026-09-27, receipt e74cc0d02de16899, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-05-12 ([filing](https://www.sec.gov/Archives/edgar/data/1267565/000110465926059018/0001104659-26-059018-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1267565/000162828026070589/0001628280-26-070589-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1267565/000162828026070585/0001628280-26-070585-index.htm)
- 8-K · filed 2026-10-19 · 1.02 Termination of a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1267565/000110465926116876/0001104659-26-116876-index.htm)
- 8-K · filed 2026-08-13 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1267565/000110465926095464/0001104659-26-095464-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1267565/000162828026053851/0001628280-26-053851-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/1267565/000162828026053849/0001628280-26-053849-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001267565.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1267565

## Cite

POPS4, Edgar & Edgarette: Collegium Pharmaceutical, Inc. (COLL) company card, from the company's own SEC filings, accessed 2026-11-12, https://www.pops4.com/boards/company/COLL. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.